Elliot Levine, MD
Advanced Heart Failure and Transplant Cardiology · Valhalla, NYNPI 1104141415
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $4,177 and has fallen 89.4% since, to $443 in 2025.
Across 108 payments — averaging $72.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$615
- Johnson & Johnson$254
- Pfizer$246
- Lilly USA, LLC$197
- Actelion Pharmaceuticals US, Inc.$189
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$3,00038%
- Travel & lodging$1,50719%
- Food & beverage$3,24041%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $5,035 |
| Abbott | 10 | $615 |
| Johnson & Johnson(2 entities) | 14 | $254 |
| Pfizer | 8 | $246 |
| Lilly USA, LLC | 7 | $197 |
| Actelion Pharmaceuticals US, Inc. | 7 | $189 |
| Abiomed | 5 | $170 |
| United Therapeutics Corporation | 1 | $142 |
| E.r. Squibb & Sons, L.L.C. | 2 | $127 |
| Cardiovascular Systems Inc. | 1 | $127 |
| Novartis | 5 | $86 |
| AstraZeneca | 5 | $82 |
| Lundbeck LLC | 3 | $81 |
| Alnylam Pharmaceuticals Inc. | 3 | $79 |
| Merck | 4 | $66 |
| Atricure, Inc. | 1 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $45 |
| IBSA Pharma Inc. | 2 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Insulet Corporation | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Sensible Medical Innovations Inc | 1 | $15 |
| AbbVie | 1 | $13 |
| KCI USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartWare HVAD$664
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$297
- HeartMate 3 Left Ventricular Dev$163
- ORENITRAM$142
- TYVASO$142
- REMODULIN$142
- VYNDAQEL$120
- ELIQUIS$107
How this compares
$7,845 in reported general payments places this provider in the 60th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 42 | $1,044,030 |
| EntrestoSacubitril/Valsartan | 226 | $269,012 |
| Orenitram ErTreprostinil Diolamine | 22 | $256,750 |
| AdempasRiociguat | 11 | $155,213 |
| EliquisApixaban | 122 | $139,997 |
| FarxigaDapagliflozin Propanediol | 131 | $116,082 |
| Ambrisentan | 21 | $107,317 |
| JardianceEmpagliflozin | 57 | $53,365 |
| Tadalafil | 27 | $29,582 |
| Torsemide | 154 | $5,442 |
| Metoprolol Succinate | 162 | $2,276 |
| Atorvastatin Calcium | 163 | $1,594 |
| Spironolactone | 138 | $1,302 |
| Carvedilol | 118 | $1,022 |
| Losartan Potassium | 86 | $916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $246 | $1,184,027164 claims |
| NovartisEntresto | $86 | $269,012226 claims |
| AstraZenecaFarxiga | $82 | $116,082131 claims |
| Boehringer IngelheimJardiance | $17 | $53,36557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Valhalla
- Stephen PanValhalla$159K
- Ravi ShahValhalla$25K
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Dor LotanNew York$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.